CARDIFF ONCOLOGY, INC.: current accounts payable
Current accounts payable for CARDIFF ONCOLOGY, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CARDIFF ONCOLOGY, INC. financial histories
What this measure means
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
Exact concept: us-gaap:AccountsPayableCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 8,087,000 | USD | 2026-02-24 | 10-K · 0001193125-26-067464 |
| At date | 2024-12-31 | 4,821,000 | USD | 2026-02-24 | 10-K · 0001193125-26-067464 |
| At date | 2023-12-31 | 1,966,000 | USD | 2025-02-27 | 10-K · 0000950170-25-028992 |
| At date | 2022-12-31 | 1,956,000 | USD | 2024-02-29 | 10-K · 0001628280-24-007948 |
| At date | 2021-12-31 | 1,439,000 | USD | 2023-03-02 | 10-K · 0001628280-23-006037 |
| At date | 2020-12-31 | 1,366,000 | USD | 2022-02-24 | 10-K · 0001628280-22-003808 |
| At date | 2019-12-31 | 656,304 | USD | 2021-02-25 | 10-K · 0001628280-21-003277 |
| At date | 2018-12-31 | 664,840 | USD | 2020-02-27 | 10-K · 0001628280-20-002424 |
| At date | 2017-12-31 | 825,244 | USD | 2019-03-06 | 10-K · 0001628280-19-002546 |
| At date | 2016-12-31 | 1,130,536 | USD | 2018-02-26 | 10-K · 0001628280-18-002226 |
| At date | 2015-12-31 | 1,040,868 | USD | 2017-03-15 | 10-K · 0001628280-17-002601 |
| At date | 2014-12-31 | 747,799 | USD | 2016-03-10 | 10-K · 0001628280-16-012562 |
| At date | 2013-12-31 | 286,608 | USD | 2015-03-12 | 10-K · 0001104659-15-019213 |
| At date | 2012-12-31 | 175,679 | USD | 2014-03-17 | 10-K · 0001104659-14-020261 |
| At date | 2011-12-31 | 928,364 | USD | 2013-04-01 | 10-K · 0001104659-13-026211 |
Related financial histories
- CARDIFF ONCOLOGY, INC.: total assets
- CARDIFF ONCOLOGY, INC.: total liabilities
- CARDIFF ONCOLOGY, INC.: stockholders equity
- CARDIFF ONCOLOGY, INC.: cash and cash equivalents
- CARDIFF ONCOLOGY, INC.: net income or loss
- CARDIFF ONCOLOGY, INC.: operating cash flow
- CARDIFF ONCOLOGY, INC.: capital expenditure payments
- CARDIFF ONCOLOGY, INC.: revenue
- CARDIFF ONCOLOGY, INC.: contract revenue excluding tax
- CARDIFF ONCOLOGY, INC.: financing cash flow
- CARDIFF ONCOLOGY, INC.: investing cash flow
- CARDIFF ONCOLOGY, INC.: retained earnings or deficit
- CARDIFF ONCOLOGY, INC.: basic weighted-average shares
- CARDIFF ONCOLOGY, INC.: diluted weighted-average shares
- CARDIFF ONCOLOGY, INC.: basic earnings per share
- CARDIFF ONCOLOGY, INC.: diluted earnings per share
- CARDIFF ONCOLOGY, INC.: net property, plant and equipment
- CARDIFF ONCOLOGY, INC.: share-based compensation expense
- CARDIFF ONCOLOGY, INC.: operating income or loss
- CARDIFF ONCOLOGY, INC.: current assets
- CARDIFF ONCOLOGY, INC.: interest expense
- CARDIFF ONCOLOGY, INC.: current liabilities
- CARDIFF ONCOLOGY, INC.: net current accounts receivable
- CARDIFF ONCOLOGY, INC.: operating expenses
- CARDIFF ONCOLOGY, INC.: cost of revenue
- CARDIFF ONCOLOGY, INC.: selling, general and administrative expense
- CARDIFF ONCOLOGY, INC.: research and development expense
Inspect the source
- Entity
- CARDIFF ONCOLOGY, INC. / CIK 0001213037
- Captured
- 2026-09-20T07:45:48.177Z
- SEC response SHA-256
5fefa7380123168da913afadb8db67f9296559e6467fa58ab3879c6c623fb326
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001213037.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))